0001410939-23-000105.txt : 20230706 0001410939-23-000105.hdr.sgml : 20230706 20230706184538 ACCESSION NUMBER: 0001410939-23-000105 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230703 FILED AS OF DATE: 20230706 DATE AS OF CHANGE: 20230706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Westby Keith CENTRAL INDEX KEY: 0001696429 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36080 FILM NUMBER: 231074829 MAIL ADDRESS: STREET 1: ONE UNIVERSITY SQUARE DRIVE, SUITE 280 CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IVERIC bio, Inc. CENTRAL INDEX KEY: 0001410939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208185347 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: (609) 474-6755 MAIL ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Ophthotech Corp. DATE OF NAME CHANGE: 20070828 4 1 wk-form4_1688683528.xml FORM 4 X0407 4 2023-07-03 0 0001410939 IVERIC bio, Inc. ISEE 0001696429 Westby Keith C/O IVERIC BIO, INC. 8 SYLVAN WAY PARSIPPANY NJ 07054 0 1 0 0 SVP, Chief Operating Officer 1 Common Stock 2023-07-03 4 M 0 20000 2.94 A 59652 D Common Stock 2023-07-03 4 S 0 20000 39.45 D 39652 D Stock Option (right to buy) 2.94 2023-07-03 4 M 0 20000 2.94 D 2027-12-18 Common Stock 20000 80000 D The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $39.37 to $39.56 per share on July 3, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. /s/ Todd D.C. Anderman, as Attorney-in-Fact for Keith Westby 2023-07-06